Preemptive cyclosporin A in immune‐mediated thrombotic thrombocytopenic purpura

Survivors of immune‐mediated thrombotic thrombocytopenic purpura (iTTP) are exposed to clinical relapses when a disintegrin and metalloproteinase with thrombospondin type 1 repeats, member 13 (ADAMTS13) activity decreases during follow‐up. Although preemptive rituximab usually improves ADAMTS13 acti...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of haematology 2023-02, Vol.110 (2), p.157-160
Hauptverfasser:	Comparon, Celine, Galicier, Lionel, Rebibou, Jean Michel, Coppo, Paul, Benhamou, Ygal
Format:	Artikel
Sprache:	eng
Schlagworte:	ADAM protein ADAMTS 13 activity ADAMTS13 Protein Autoantibodies Cyclosporin A Cyclosporine - adverse effects cyclosporine A Cyclosporins Humans immunology Intolerance Original Patients Purpura Purpura, Thrombotic Thrombocytopenic - diagnosis Purpura, Thrombotic Thrombocytopenic - drug therapy Recurrence Remission Rituximab Rituximab - therapeutic use Thrombocytopenic purpura Thrombospondin Thrombotic thrombocytopenic purpura
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!